Novavax to Host Conference Call and Webcast to Provide Corporate Update and Report of Fourth Quarter and Year-End 2017 Financ...
March 07 2018 - 4:05PM
GAITHERSBURG, Md., March 07, 2018
(GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it
will provide a corporate update and report its fourth quarter and
full year 2017 financial and operating results following the close
of U.S. financial markets on Wednesday, March 14, 2018.
Conference call and webcast details are as follows: |
|
|
Date: |
March
14, 2018 |
Time: |
5:00
p.m. U.S. Eastern Time (ET) |
Dial-in
number: |
(877)
212-6076 (Domestic) or (707) 287-9331 (International) |
Passcode: |
6472939 |
Webcast: |
www.novavax.com, "Investors"/ "Events" |
|
|
Conference call and webcast replay: |
|
Dates: |
Starting at 8:00 p.m. ET, March 14, 2018 until |
|
9:00
p.m. ET March 21, 2018 |
Dial-in
number: |
(855)
859-2056 (Domestic) or (404) 537-3406 (International) |
Passcode: |
6472939 |
Webcast: |
www.novavax.com, "Investors"/ "Events", until June 14, 2018 |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a
clinical-stage biotechnology company committed to delivering novel
products to prevent infectious diseases. Our RSV and influenza
nanoparticle vaccine candidates are Novavax' most advanced clinical
programs and are at the forefront of the Company's efforts to
improve global health. Additional information about Novavax is
available on the Company's website, novavax.com.
Contact:
Investors
Westwicke Partners
John Woolford
john.woolford@westwicke.com
443-213-0506
Media
Sam Brown
Mike Beyer
mikebeyer@sambrown.com
312-961-2502
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Novavax, Inc. via Globenewswire
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024